Recon: FDA warns Evusheld ineffective against emerging Omicron subvariant; Production woes prompt Takeda to discontinue hypoparathyroidism drug

ReconReconBiologicsBiotechnologyDiagnosticsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy